{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:38:09Z","timestamp":1792813089429,"version":"4.5.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.mayocp.2019.01.018","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T07:01:45Z","timestamp":1561964505000},"page":"1357-1373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":387,"title":["Ulcerative Colitis"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6126-3814","authenticated-orcid":false,"given":"Joseph D.","family":"Feuerstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan C.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A.","family":"Farraye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocp.2019.01.018_bib1","first-page":"264","article-title":"Morbid appearances in the intestine of Miss Bankes","volume":"2","author":"Wilks","year":"1859","journal-title":"London Med Times Gazette"},{"issue":"18","key":"10.1016\/j.mayocp.2019.01.018_bib2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10080","key":"10.1016\/j.mayocp.2019.01.018_bib3","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG clinical guideline: preventive care in inflammatory bowel disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.mayocp.2019.01.018_bib5","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/ibd.22839","article-title":"Ulcerative colitis as a progressive disease: the forgotten evidence","volume":"18","author":"Torres","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"10114","key":"10.1016\/j.mayocp.2019.01.018_bib6","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib8","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/gutjnl-2012-303661","article-title":"Geographical variability and environmental risk factors in inflammatory bowel disease","volume":"62","author":"Ng","year":"2013","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.mayocp.2019.01.018_bib9","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2009.04.001","article-title":"Increased short- and long-term risk of inflammatory bowel disease after Salmonella or Campylobacter gastroenteritis","volume":"137","author":"Gradel","year":"2009","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2036.2005.02564.x","article-title":"Risk factors for inflammatory bowel disease in the general population","volume":"22","author":"Garc\u00eda Rodr\u00edguez","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib12","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1053\/j.gastro.2008.05.081","article-title":"Infectious gastroenteritis and risk of developing inflammatory bowel disease","volume":"135","author":"Porter","year":"2008","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.mayocp.2019.01.018_bib13","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/ajg.2010.398","article-title":"Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease","volume":"105","author":"Shaw","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib14","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1542\/peds.2011-3886","article-title":"Antibiotic exposure and IBD development among children: a population-based cohort study","volume":"130","author":"Kronman","year":"2012","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.018_bib15","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7326\/0003-4819-156-5-201203060-00007","article-title":"Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study","volume":"156","author":"Ananthakrishnan","year":"2012","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.mayocp.2019.01.018_bib16","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/j.1572-0241.2008.02064.x","article-title":"The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis","volume":"103","author":"Cornish","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.018_bib17","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1053\/j.gastro.2012.07.096","article-title":"Hormone therapy increases risk of ulcerative colitis but not Crohn's disease","volume":"143","author":"Khalili","year":"2012","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.mayocp.2019.01.018_bib18","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/MEG.0000000000000915","article-title":"Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies","volume":"29","author":"Ortizo","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.mayocp.2019.01.018_bib19","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/ajg.2010.124","article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a case-control study","volume":"105","author":"Crockett","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.mayocp.2019.01.018_bib20","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1038\/ajg.2009.417","article-title":"Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study","volume":"104","author":"Bernstein","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/ajg.2014.8","article-title":"Isotretinoin and risk of inflammatory bowel disease: a French nationwide study","volume":"109","author":"Racine","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib22","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/ajg.2015.50","article-title":"Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011","volume":"110","author":"Moller","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"7422","key":"10.1016\/j.mayocp.2019.01.018_bib23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/j.gastro.2013.05.050","article-title":"Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics","volume":"145","author":"Ventham","year":"2013","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.mayocp.2019.01.018_bib25","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.4065\/81.11.1462","article-title":"Smoking and inflammatory bowel disease: a meta-analysis","volume":"81","author":"Mahid","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.mayocp.2019.01.018_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000121412","article-title":"Diet in the aetiology of ulcerative colitis: a European prospective cohort study","volume":"77","author":"Hart","year":"2008","journal-title":"Digestion"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib27","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1572-0241.2000.01942.x","article-title":"Diet as a risk factor for the development of ulcerative colitis","volume":"95","author":"Geerling","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.018_bib28","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.gastro.2013.07.050","article-title":"A\u00a0prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis","volume":"145","author":"Ananthakrishnan","year":"2013","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.mayocp.2019.01.018_bib29","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJM200103153441104","article-title":"Appendectomy and protection against ulcerative colitis","volume":"344","author":"Andersson","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2019.01.018_bib30","doi-asserted-by":"crossref","first-page":"f432","DOI":"10.1136\/bmj.f432","article-title":"Ulcerative colitis","volume":"346","author":"Ford","year":"2013","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.mayocp.2019.01.018_bib31","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1097\/MIB.0000000000000429","article-title":"Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss Inflammatory Bowel Disease Cohort","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"4947","key":"10.1016\/j.mayocp.2019.01.018_bib33","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis: final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib34","first-page":"263","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis, part 1: definitions and diagnosis (Spanish version) [in Spanish]","volume":"79","author":"Dignass","year":"2014","journal-title":"Rev Gastroenterol Mex"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/ibd.21815","article-title":"Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts","volume":"18","author":"Magro","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.mayocp.2019.01.018_bib36","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.mayocp.2019.01.018_bib37","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrgastro.2013.117","article-title":"Extraintestinal manifestations and complications in IBD","volume":"10","author":"Ott","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.clindermatol.2007.10.018","article-title":"Skin manifestations of inflammatory bowel disease","volume":"26","author":"Timani","year":"2008","journal-title":"Clin Dermatol"},{"issue":"6","key":"10.1016\/j.mayocp.2019.01.018_bib39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11894-008-0108-6","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"10","author":"Williams","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.018_bib40","first-page":"631","article-title":"The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis","volume":"11","author":"Karreman","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"issue":"8","key":"10.1016\/j.mayocp.2019.01.018_bib41","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.mayocp.2019.01.018_bib42","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.berh.2006.03.010","article-title":"Ankylosing spondylitis and bowel disease","volume":"203","author":"Rudwaleit","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11926-000-0045-3","article-title":"Arthritis and inflammatory bowel disease","volume":"2","author":"Wordsworth","year":"2000","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-017-0251-7","article-title":"Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment","volume":"18","author":"Alavi","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.018_bib45","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"9904","key":"10.1016\/j.mayocp.2019.01.018_bib46","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","article-title":"Primary sclerosing cholangitis","volume":"382","author":"Hirschfield","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.mayocp.2019.01.018_bib47","first-page":"1275","article-title":"Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study","volume":"92","author":"D'Haens","year":"1997","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.mayocp.2019.01.018_bib48","doi-asserted-by":"crossref","first-page":"704","DOI":"10.7326\/M13-2403","article-title":"Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis","volume":"160","author":"Danese","year":"2014","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib49","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1572-0241.2001.03613.x","article-title":"Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease","volume":"96","author":"Peeters","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.mayocp.2019.01.018_bib50","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1111\/j.1572-0241.2004.40369.x","article-title":"Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype","volume":"99","author":"Zholudev","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib51","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ajg.2015.6","article-title":"A\u00a0meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS","volume":"110","author":"Menees","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.018_bib52","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1053\/j.gastro.2015.07.003","article-title":"Biomarkers of inflammation in inflammatory bowel disease","volume":"149","author":"Sands","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib53","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/gut.2005.069476","article-title":"Laboratory markers in IBD: useful, magic, or unnecessary toys?","volume":"55","author":"Vermeire","year":"2006","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.018_bib54","first-page":"893","article-title":"The role of mesalamine in the treatment of ulcerative colitis","volume":"3","author":"Karagozian","year":"2007","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"10.1016\/j.mayocp.2019.01.018_bib55","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/ibd.23024","article-title":"Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis","volume":"18","author":"Feagan","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.mayocp.2019.01.018_bib56","first-page":"CD004118","article-title":"Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","volume":"11","author":"Marshall","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib57","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2036.1995.tb00384.x","article-title":"Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis","volume":"9","author":"Marshall","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"issue":"8241","key":"10.1016\/j.mayocp.2019.01.018_bib58","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0140-6736(81)90523-7","article-title":"Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas","volume":"2","author":"Campieri","year":"1981","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ajg.2011.410","article-title":"Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis","volume":"107","author":"Ford","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib60","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ajg.2011.67","article-title":"Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.018_bib61","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2012.08.003","article-title":"Once-daily budesonide MMX\u00ae extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.018_bib62","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/apt.13076","article-title":"Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies","volume":"41","author":"Sandborn","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.mayocp.2019.01.018_bib63","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/MIB.0000000000001153","article-title":"Variations in health insurance policies regarding biologic therapy use in inflammatory bowel disease","volume":"23","author":"Yadav","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2019.01.018_bib64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.mayocp.2019.01.018_bib65","first-page":"CD000478","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","volume":"1","author":"Timmer","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib66","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib67","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1586\/egh.09.24","article-title":"Management of acute severe ulcerative colitis","volume":"3","author":"Doherty","year":"2009","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib68","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ajg.2016.7","article-title":"Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids","volume":"111","author":"Narula","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib69","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1053\/j.gastro.2006.01.047","article-title":"American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease","volume":"130","author":"Lichtenstein","year":"2006","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib70","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/ajg.2011.64","article-title":"Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis","volume":"106","author":"Khan","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib71","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2036.2009.04023.x","article-title":"Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis","volume":"30","author":"Gisbert","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.mayocp.2019.01.018_bib72","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11894-007-0068-2","article-title":"Optimizing drug therapy in inflammatory bowel disease","volume":"9","author":"Swaminath","year":"2007","journal-title":"Curr Gastroenterol Rep"},{"issue":"9","key":"10.1016\/j.mayocp.2019.01.018_bib73","doi-asserted-by":"crossref","first-page":"716","DOI":"10.7326\/0003-4819-129-9-199811010-00007","article-title":"Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine","volume":"129","author":"Black","year":"1998","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.018_bib74","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1053\/j.gastro.2004.09.061","article-title":"Use of laboratory testing to guide 6-mercaptopurine\/azathioprine therapy","volume":"127","author":"Lichtenstein","year":"2004","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib75","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"15","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.018_bib76","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/MPG.0000000000001077","article-title":"EBV status and thiopurine use in pediatric IBD","volume":"62","author":"Gordon","year":"2016","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"5, suppl 1","key":"10.1016\/j.mayocp.2019.01.018_bib77","doi-asserted-by":"crossref","first-page":"S581","DOI":"10.1016\/S0016-5085(17)32095-4","article-title":"EBV status and immunosuppressant use in patients with IBD who subsequently develop lymphoma: a retrospective and prospective study [abstract]","volume":"152","author":"Lam","year":"2017","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib78","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/MIB.0000000000001031","article-title":"Do thiopurines reduce the risk of surgery in elderly onset inflammatory bowel disease? a 20-year national population-based cohort study","volume":"23","author":"Alexakis","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2019.01.018_bib79","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A\u00a0systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.mayocp.2019.01.018_bib80","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMct1209614","article-title":"Tumor necrosis factor inhibitors for inflammatory bowel disease","volume":"369","author":"Nielsen","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.mayocp.2019.01.018_bib81","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2019.01.018_bib82","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.mayocp.2019.01.018_bib83","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib84","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mayocp.2019.01.018_bib85","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib86","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/apt.14422","article-title":"Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis","volume":"47","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.mayocp.2019.01.018_bib87","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.crohns.2014.01.010","article-title":"Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients na\u00efve to anti-TNF therapy: an indirect treatment comparison meta-analysis","volume":"8","author":"Thorlund","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib88","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.mayocp.2019.01.018_bib89","first-page":"690","article-title":"Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme","volume":"11","author":"Razanskaite","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib90","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/apt.14453","article-title":"Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study","volume":"47","author":"Schmitz","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mayocp.2019.01.018_bib91","series-title":"Treatment of Inflammatory Bowel Disease with Biologics","year":"2017"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib93","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/gut.2005.088732","article-title":"Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?","volume":"56","author":"Rutgeerts","year":"2007","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.mayocp.2019.01.018_bib94","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1136\/gutjnl-2012-302830","article-title":"Mucosal healing in inflammatory bowel diseases: a systematic review","volume":"61","author":"Neurath","year":"2012","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib95","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.giec.2014.03.005","article-title":"Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity","volume":"24","author":"Walsh","year":"2014","journal-title":"Gastrointest Endosc Clin N Am"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib96","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2017.07.031","article-title":"American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases","volume":"153","author":"Vande Casteele","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.018_bib97","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ajg.2017.21","article-title":"Therapeutic drug monitoring in IBD: the new standard-of-care for anti-TNF therapy","volume":"112","author":"Papamichael","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib98","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.mayocp.2019.01.018_bib99","first-page":"677","article-title":"Cyclosporine versus infliximab for the treatment of severe ulcerative colitis","volume":"7","author":"Kornbluth","year":"2011","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"26","key":"10.1016\/j.mayocp.2019.01.018_bib100","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib101","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/gut.52.2.172","article-title":"Cyclosporin for refractory ulcerative colitis","volume":"52","author":"Loftus","year":"2003","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.mayocp.2019.01.018_bib102","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2019.01.018_bib103","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMe1307415","article-title":"Inhibition of leukocyte trafficking in inflammatory bowel disease [editorial]","volume":"369","author":"Cominelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2019.01.018_bib104","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/apt.14215","article-title":"Editorial: how effective is vedolizumab in the \u2018real world\u2019?","volume":"46","author":"Speight","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.018_bib105","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"issue":"18","key":"10.1016\/j.mayocp.2019.01.018_bib106","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2019.01.018_bib107","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2019.01.018_bib108","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gut.2003.037747","article-title":"Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine","volume":"53","author":"Kruis","year":"2004","journal-title":"Gut"},{"issue":"9179","key":"10.1016\/j.mayocp.2019.01.018_bib109","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(98)06343-0","article-title":"Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial","volume":"354","author":"Rembacken","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2019.01.018_bib110","first-page":"CD005573","article-title":"Probiotics for induction of remission in ulcerative colitis","volume":"4","author":"Mallon","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.mayocp.2019.01.018_bib111","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/ajg.2010.218","article-title":"Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study","volume":"105","author":"Tursi","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.mayocp.2019.01.018_bib112","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.cgh.2009.07.016","article-title":"The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis","volume":"7","author":"Sood","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"15","key":"10.1016\/j.mayocp.2019.01.018_bib113","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3748\/wjg.v16.i15.1908","article-title":"Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis","volume":"16","author":"Sang","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.mayocp.2019.01.018_bib114","first-page":"CD007443","article-title":"Probiotics for maintenance of remission in ulcerative colitis","volume":"12","author":"Naidoo","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.mayocp.2019.01.018_bib115","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis, part 2: current management","volume":"6","author":"Dignass","year":"2012","journal-title":"J\u00a0Crohns Colitis"},{"issue":"6","key":"10.1016\/j.mayocp.2019.01.018_bib116","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.suc.2015.07.003","article-title":"Indications and options for surgery in ulcerative colitis","volume":"95","author":"Bohl","year":"2015","journal-title":"Surg Clin North Am"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib117","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10620-018-4922-x","article-title":"Mortality is rare following elective and non-elective surgery for ulcerative colitis, but mild postoperative complications are common","volume":"63","author":"Feuerstein","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"12","key":"10.1016\/j.mayocp.2019.01.018_bib118","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.cgh.2013.03.033","article-title":"Pouchitis: what every gastroenterologist needs to know","volume":"11","author":"Shen","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.mayocp.2019.01.018_bib119","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2004-823070","article-title":"Complications of ileoanal pouches","volume":"17","author":"Gorgun","year":"2004","journal-title":"Clin Colon Rectal Surg"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib120","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1053\/j.gastro.2009.12.035","article-title":"AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease","volume":"138","author":"Farraye","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mayocp.2019.01.018_bib121","series-title":"Ulcerative Colitis from Genetics to Complications","first-page":"77","article-title":"Colorectal cancer in ulcerative colitis patients","author":"Feuerstein","year":"2011"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib122","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/j.gastro.2012.04.016","article-title":"Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years","volume":"143","author":"Jess","year":"2012","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.mayocp.2019.01.018_bib123","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.12651","article-title":"Systematic review with meta analysis: the declining risk of colorectal cancer in ulcerative colitis","volume":"39","author":"Casta\u00f1o-Milla","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib124","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1053\/j.gastro.2009.12.037","article-title":"AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease","volume":"138","author":"Farraye","year":"2010","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib125","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.gie.2014.12.009","article-title":"SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease","volume":"81","author":"Laine","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.mayocp.2019.01.018_bib126","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.gie.2014.10.030","article-title":"American Society for Gastrointestinal Endoscopy Standards of Practice Committee. The role of endoscopy in inflammatory bowel disease","volume":"81","author":"Shergill","year":"2015","journal-title":"Gastrointest Endosc"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib127","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib128","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ajg.2013.451","article-title":"Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis","volume":"109","author":"Ariyaratnam","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib129","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1440-1746.2011.06865.x","article-title":"Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study","volume":"27","author":"Setshedi","year":"2012","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib130","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","volume":"8","author":"Long","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"23","key":"10.1016\/j.mayocp.2019.01.018_bib131","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Andersen","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mayocp.2019.01.018_bib132","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cgh.2015.07.037","article-title":"Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents","volume":"14","author":"Axelrad","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.mayocp.2019.01.018_bib133","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/ibd.20959","article-title":"Lack of association between cervical dysplasia and IBD: a large case-control study","volume":"15","author":"Lees","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib134","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1572-0241.2007.01582.x","article-title":"Higher incidence of abnormal Pap smears in women with inflammatory bowel disease","volume":"103","author":"Kane","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.018_bib135","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2036.2008.03766.x","article-title":"Screening differences and risk of cervical cancer in inflammatory bowel disease","volume":"28","author":"Hutfless","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.mayocp.2019.01.018_bib136","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/MIB.0000000000000338","article-title":"Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia\/cancer? a meta-analysis","volume":"21","author":"Allegretti","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.mayocp.2019.01.018_bib137","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ajog.2015.10.147","article-title":"Cervical cancer screening: evidence behind the guidelines","volume":"214","author":"Lees","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.mayocp.2019.01.018_bib138","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MPG.0000000000000730","article-title":"Survey of immunization practices in patients with inflammatory bowel disease among pediatric gastroenterologists","volume":"61","author":"Lester","year":"2015","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"12","key":"10.1016\/j.mayocp.2019.01.018_bib139","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1002\/ibd.21667","article-title":"Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge","volume":"17","author":"Wasan","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.mayocp.2019.01.018_bib140","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/j.1572-0241.2006.00646.x","article-title":"Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses","volume":"101","author":"Melmed","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.mayocp.2019.01.018_bib141","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.MIB.0000437737.68841.87","article-title":"Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement","volume":"20","author":"Wasan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.mayocp.2019.01.018_bib142","first-page":"33","article-title":"Vaccination considerations for patients with inflammatory bowel disease","author":"Boroujerdi-Rad","year":"2011","journal-title":"Pract Gastroenterol"},{"issue":"6","key":"10.1016\/j.mayocp.2019.01.018_bib143","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/ajg.2009.733","article-title":"A\u00a0practical guide to vaccinating the inflammatory bowel disease patient","volume":"105","author":"Wasan","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"12, suppl","key":"10.1016\/j.mayocp.2019.01.018_bib144","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.amjgastroenterol.2003.11.003","article-title":"Evaluation of bone mineral density in inflammatory bowel disease: current safety focus","volume":"98","author":"Lichtenstein","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.mayocp.2019.01.018_bib145","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/MIB.0000000000000620","article-title":"Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases","volume":"22","author":"Mikocka-Walus","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1016\/j.mayocp.2019.01.018_bib146","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/ibd.22916","article-title":"Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors","volume":"18","author":"Goodhand","year":"2012","journal-title":"Inflamm Bowel Dis"}],"updated-by":[{"DOI":"10.1016\/j.mayocp.2019.08.008","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000}}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619300849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619300849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T11:13:47Z","timestamp":1663845227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619619300849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":145,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0025619619300849"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.018","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ulcerative Colitis","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}